WH Group (OTC:WHGLY) Stock, Quote.Headers.trade-ideas

WH Group is a holding company and the world's largest vertically integrated producer of pork and related packaged meat products. Its revenue is mainly derived from activities undertaken by its China and US operations, which are respectively via 70.3%-owned Henan Shuanghui Investment & Development Co., or Shuanghui, and wholly owned Smithfield Foods Inc. In the US, its key packaged meats brands, in which it has an 8% market share, include Nathan's hot dogs, Armour, John Morrell, and Curly's, while in China, products are mainly under the Shuanghui brand, where it also has a 32% market share. We expect the company's operating profit to be split almost equally between the US and China going forward with a small contribution from Europe.

Penny Stocks

WHGLY

WHGRF

Key Takeaways:


	WH Group plans to list its Smithfield pork subsidiary as early as this year in a U.S. IPO that could raise $1 billion or more
	Potential Chinese anti-dumping tariffs against European pork could throw a spanner into the company’s recent European expansion 


By Lee Shih Ta

WH Group Serves Up Smithfield Spinoff To Support Overseas Expansion

Stuttgart,,Germany,-,Jan,08,,2022:,Cellphone,With,Logo,Of

News

IPOs

Markets

General

The group acquired Smithfield in 2013, and the combined firm went public in Hong Kong in 2014 after raising more than $2 billion.

Hong Kong&#39;s WH Group Subsidiary Smithfield Foods Gears Up For $1B IPO In US: Report (UPDATED)

Asia

Key Takeaways:


	WH Group reported its first-quarter profit rose 73% year-on-year to $301 million, though its quarterly revenue slumped 8.3%
	The improving performance follows a major restructuring of the U.S. operations for one of China’s leading pork producers


By Lau Chi Hang

WH Group Brings Back The Bacon With Rising Profits

WH Group Ltd

<p>It might seem strange to say a stock is still irresistible after it&#39;s rallied 350% and just closed at a new high, but it&#39;s hard not to with <strong>Netflix, Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nflx#NASDAQ">NFLX</a>). For a company that had to watch its shares lose 80% of their value just 2 years ago, it&#39;s been a remarkable turnaround and one that looks likely to continue.&nbsp;</p>
<p>During the pandemic-fuelled bull run, Netflix found itself a key member of the much-acclaimed FAANG group of tech stocks. But as the bubble started to pop around November 2022, they were the stock that fell the hardest and further. For investors who managed to ride out that volatility or who have been able to get involved during an earlier phase of the current rally, it must be a particularly sweet turn of events.&nbsp;</p>
<p>As we round the corner into the last few months of the year, it&#39;s Netflix&#39;s shares that have tacked on the most value in the past 12 months and, in many ways, look the strongest heading into 2025. So what&#39;s behind the recent success of the streaming giant, and what makes them still so irresistible?&nbsp;</p>
<h2>Bullish Fundamentals&nbsp;</h2>
<p>Well for starters, the company has managed to turn its fundamental performance around, and absolutely crushed analyst expectations for its most recent earnings report. It was their highest ever revenue print and one of their most profitable quarters ever. This momentum has continued into October, with fresh headlines this week showing the company&#39;s UK subsidiary closed out 2023 with a record revenue of more than $2 billion.&nbsp;</p>
<p>The analysts have not lost sight of this strong fundamental performance, either. Since the end of the summer, they have been making a steady stream of bullish calls on Netflix shares. Both Evercore and Pivotal had Buy ratings at the end of August, the latter giving the stock a street-high price target of $900.&nbsp;</p>
<p>These were added to this week by the teams over at Piper Sandler, TD Cowen and JPMorgan Chase, who all reiterated their Buy ratings on Netflix shares as well. Even though their price targets aren&#39;t quite as lofty as Pivotals, which points to a targeted upside of some 25%, they were both well ahead of the $727 that the stock closed at on Wednesday evening.&nbsp;</p>
<h2>Optimistic Outlook for Netflix</h2>
<p>Much of the bullish narrative revolves around Netflix&#39;s impressive subscriber growth, which has been landing in ahead of expectations and is on track to hit 370 million this year. There&#39;s also Netflix&#39;s strong positioning from a market share perspective, with bullish analysts seeing it as the premier dominant paid global streaming service.&nbsp;</p>
<p>In addition, the company&#39;s growth in both average revenue per user and free cash flow have both been earmarked as key tailwinds that should continue powering the stock&#39;s to highs in the coming months. Evercore even went so far as to say that Netflix is in &quot;the strongest position financially, fundamentally, and competitively&quot; that they have ever seen.&nbsp;</p>
<h2>Getting Involved with Netflix Stock</h2>
<p>However, that&#39;s not to say investors should expect it to be all plain sailing. While the majority of analysts are bullish on Netflix, there are some who have taken a more cautious stance. Earlier this week saw the team at Barclays downgrade their rating on Netflix shares to a rare Sell. In a note to investors they wrote &quot;Netflix&#39;s premium valuation is predicated on revenue growth being at least in the low double-digit range, which in our view, will get increasingly difficult&quot;.&nbsp;</p>
<p>And while the past month has seen the likes of Rosenblatt Securities and China Renaissance stop short of rating the stock a full Buy with their updates, they held off moving Netflix to a Sell, choosing instead to rate it a Neutral. It&#39;s something for investors to consider, but it&#39;s worth pointing out that these more bearish calls are very much in the minority. Looking at MarketBeat&#39;s analyst forecast tool, we can see that out of 36 analyst ratings on Netflix, only 7% rate it a Sell, while close to 70% rate it a Buy.&nbsp;</p>
<p>Based at the current price action ahead of next week&#39;s earnings report, it&#39;s fair to say that Wall Street has no hesitations about continuing to buy into Netflix at these levels.</p>
<p>The article &quot;<a href="https://www.marketbeat.com/stock-ideas/why-netflix-is-irresistible-even-at-all-time-highs/">Why Netflix Is Irresistible Even At All-Time Highs&nbsp;</a>&quot; first appeared on MarketBeat.</p>


Earnings

Entertainment

Large Cap

Price Target

Analyst Ratings

Trading Ideas

NFLX

Why Netflix Is Irresistible Even At All-Time Highs

<p><a href="https://www.federalreserve.gov/newsevents/speech/bowman20241011a.htm" title="https://www.federalreserve.gov/newsevents/speech/bowman20241011a.htm">https://www.federalreserve.gov/newsevents/speech/bowman20241011a.htm</a></p>


Federal Reserve

Fed's Bowman Does Not Comment On Monetary Policy Or Economic Outlook In Prepared Remarks On Community Banking In Chicago

<p>Cantor Fitzgerald  analyst Olivia Brayer   reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Neutral and maintains $220 price target.</p>


Reiteration

ALNY

Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target

<p><strong>Seagate Technology Holdings plc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stx#NASDAQ">STX</a>) is a leading provider of data storage technology and infrastructure solutions.</p>
<p>Seagate reported revenues of $6.55 billion in fiscal 2024. In the fiscal fourth quarter of 2024, non-GAAP revenues of $1.89 billion beat the Zacks Consensus Estimate by 1.5%. The figure increased 18% on a year-over-year basis and 14% sequentially driven by growing demand for mass capacity solutions. Management projected revenues to be $1.85 billion (+/- $150 million) for the fiscal fourth quarter.</p>
<h2>STX Witnesses Solid Demand for Mass Capacity</h2>
<p>Seagate is witnessing mass capacity demand improvement with nearline cloud demand picking up pace. In the last reported quarter, mass capacity revenues surged 46% year over year to $1.44 billion, owing to stronger global cloud demand. Sequentially, mass capacity revenues were up 22%.</p>
<p>Strengthening the global cloud demand environment is fueling demand for nearline capacity demand. In the last reported quarter, nearline cloud revenues more than doubled year over year, owing to higher traditional cloud computing workloads and new AI deployments. STX expects this momentum to continue in fiscal 2025.</p>
<p>Also, cloud service providers are focusing more on the development of AI applications while building cloud infrastructure. This includes training of large language models and expansion of the entire hardware stack to cushion generative AI content-driven growth. Seagate believes HDDs will play a key role in enabling these stages of the AI adoption curve and expects HDD demand to pick up pace going ahead.</p>
<p>Seagate&#39;s launch of the Mozaic 3+ hard drive platform, featuring Heat-Assisted Magnetic Recording (HAMR) technology, is also expected to aid in capturing a greater share in the market of mass capacity storage solutions.</p>
<p>Seagate expects HAMR to aid in exploiting megatrends like AI and machine learning, which will drive long-term demand for cost-effective mass-capacity storage solutions. The company has completed multiple qualifications for its 24TB CMR / 28TB SMR drives. It expects to begin volume shipments in the first quarter of fiscal 2025.</p>
<h2>STX&#39;s Mass Capacity Exabyte Shipments</h2>
<p>Mass capacity exabyte shipments represent more than 90% of total exabyte shipments. In the last reported quarter, the company shipped 103.9 exabytes for the mass-capacity storage market (including nearline, video and image applications and network-attached storage). This recorded a year-over-year increase of 38% in exabyte shipments and 17% sequentially.</p>
<h2>STX&#39;s Robust Outlook</h2>
<p>Driven by incremental improvements in mass-capacity demand, management anticipates first-quarter fiscal 2025 revenues to be $2.10 billion (+/- $150 million).<br />
Gross margin is expected to benefit from a higher mix of mass-capacity revenues and ongoing pricing actions. Non-GAAP earnings for the fiscal first quarter of 2025 are expected to be $1.40 per share (+/- 20 cents).</p>
<p>The non-GAAP operating expenses are expected to be $270 million. At the midpoint of the revenue guidance, management expects the non-GAAP operating margin to grow in the high-teens percentage range of revenues. Management anticipates fiscal 2025 capex to be at or below the low end of its long-term target range of 4-6% of revenues.</p>
<p>However, for VIA, management anticipates sales to fluctuate in the second half of the calendar 2024. Though smart cities are the biggest end-market opportunity, the near-term budget visibility remains blurry amid existing macroeconomic uncertainty.</p>
<h2>STX Needs to Watch Out for Cut-throat Competitive Landscape</h2>
<p>The increasing demand trends offer all players a lucrative opportunity to drive growth thereby resulting in intense competition. Stiff competition can put pricing pressure which can affect margin performance.</p>
<p>Seagate faces tough competition from other players like<strong> Western Digital Corporation </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wdc#NASDAQ">WDC</a>), <strong>NetApp Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntap#NASDAQ">NTAP</a>) and <strong>Pure Storage, Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>) in the data storage industry including HDD and SSD manufacturers. It also faces competition from companies engaged in offering storage subsystems, like electronic manufacturing services and contract electronic manufacturing.</p>
<p>Headquartered in San Jose, CA, WDC is a leading developer and manufacturer of data storage devices and solutions based on NAND flash and hard disk drive technologies. Western Digital is well-positioned to gain from continued momentum in its HDD and Flash businesses. In the fiscal fourth quarter of 2024, sales from the Cloud end market climbed 89% year over year due to higher demand for its nearline HDDs and enterprise SSDs, along with improved pricing.</p>
<p>NetApp provides enterprise storage as well as data management software and hardware products and services. It assists enterprises in managing multiple cloud environments, adopting next-generation technologies like artificial intelligence, Kubernetes and contemporary databases, and navigating the complexity brought by the quick development of data and cloud usage. NetApp&#39;s performance is being driven by strong demand for an all-flash portfolio and growth in first-party and marketplace cloud storage services. All-Flash Array Business&#39; annualized ARR was $3.4 billion, up 21% in the first quarter of 2025.</p>
<p>Headquartered in Mountain View, CA, PSTG provides software-defined all-flash solutions that are uniquely fast and cloud-capable for customers. Pure Storage&#39;s primary offerings are FlashArray and FlashBlade products, which include FlashArray//C, FlashArray//XL, FlashArray File Services, FlashBlade//S and FlashBlade//E. Momentum in its FlashBlade solutions, including FlashBlade//E and subscription-based offerings, is cushioning Pure Storage&#39;s performance. Healthy subscription services revenues (with 25% year-over-year growth in the second-quarter fiscal 2025) are tailwinds. In the last reported quarter, revenues soared 11% year over year and beat the Zacks Consensus Estimate by 1%.</p>
<p><a href="https://www.zacks.com/stock/news/2348985/will-seagate-continue-to-gain-from-increasing-mass-capacity-demand?cid=CS-BENZ-FT-analyst_blog|company_news_tech_sector-2348985">To read this article on Zacks.com click here.</a></p>


Guidance

Offerings

Management

Tech

NTAP

PSTG

Will Seagate Continue to Gain From Increasing Mass Capacity Demand?

<p>Cantor Fitzgerald  analyst Derek Soderberg   reiterates Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) with a Overweight and maintains $60 price target.</p>


Cantor Fitzgerald Reiterates Overweight on Symbotic, Maintains $60 Price Target

<p>Roth MKM  analyst Suji Desilva   reiterates Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and maintains $200 price target.</p>


Roth MKM Reiterates Buy on Advanced Micro Devices, Maintains $200 Price Target

<p>Cantor Fitzgerald  analyst Prakhar Agrawal   reiterates Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Neutral.</p>


MDGL

Cantor Fitzgerald Reiterates Neutral on Madrigal Pharmaceuticals

<p><strong>Needham </strong>analyst Kyle Peterson initiated coverage on <strong>Axos Financial, Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) with a Buy rating <a target="_blank" href="https://www.benzinga.com/quote/AX/analyst-ratings" rel="noreferrer noopener">and a price target of $82.00</a>.</p>
<p>The analyst writes that, unlike traditional banks, the company avoids a broad branch strategy, enhancing profitability and efficiency while expanding its total addressable market.</p>
<p>Importantly, Axos Financial holds a full banking license, which offers stickier and cheaper funding for loans compared to warehouse lines and enables in-house banking products, adds the analyst.</p>
<p>The analyst says that Axos Financial was &#8220;ahead of its time&#8221; by prioritizing a digital-first strategy over building a branch network. Positive secular trends toward digital banking have allowed AX to establish itself effectively.</p>
<p>Peterson says that Axos Financial&#8217;s corporate culture distinguishes it from traditional banks, enabling the company to expand its total addressable market (TAM) and achieve efficient growth.</p>
<p>Axos Financial&#8217;s exceptional profitability stems from its robust underwriting and credit performance, as well as a streamlined expense structure, adds the analyst.</p>
<p>Peterson projects EPS of $7.05 in 2025 and $7.40 in 2026.</p>
<p>Investors can gain exposure to the stock via&nbsp;<strong>Principal U.S. Small-Cap ETF </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSC#NASDAQ">PSC</a>) and <strong>WisdomTree U.S. SmallCap Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EES#NYSE">EES</a>).</p>
<p><strong>Price Action</strong>: AX shares are up 5.25% at $63.58 at the last check Friday<strong>.</strong></p>
<p><em>Photo via Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/09/40774169/implied-volatility-surging-for-axos-financial-stock-options" target="_blank" rel="noreferrer noopener">Implied Volatility Surging for Axos Financial Stock Options</a></strong></li>
</ul>


Analyst Color

Equities

Mid Cap

Initiation

Movers

Axos Financial 'Ahead of Its Time,' Analyst Applauds Digital-First Strategy

<p>Roth MKM  analyst Mike Niehuser   maintains Contango Ore (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTGO#AMEX">CTGO</a>) with a Buy and raises the price target from $33 to $37.</p>


CTGO

Roth MKM Maintains Buy on Contango Ore, Raises Price Target to $37

<p>Cantor Fitzgerald  analyst Andres Sheppard   reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Neutral and maintains $245 price target.</p>


TSLA

Cantor Fitzgerald Reiterates Neutral on Tesla, Maintains $245 Price Target

<p>Cantor Fitzgerald  analyst Louise Chen   reiterates Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) with a Overweight.</p>


ZVRA

Cantor Fitzgerald Reiterates Overweight on Zevra Therapeutics

<p>Driven by demand from cloud computing and AI, semiconductor sales have skyrocketed in recent months as pressure due to supply chain concerns and inflation has eased. The specialized chips that power these popular technologies are in such high demand that makers of these products now represent three of the 10 largest companies in the world by market capitalization&mdash;NVIDIA Corp., Taiwan Semiconductor Manufacturing Co. Ltd., and <strong>Broadcom Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avgo#NASDAQ">AVGO</a>), each of which has a market cap of at least $833 billion.</p>
<p>Notably, the semiconductor market appears to be still heating up. Global semiconductor sales for August 2024 reached more than $53 billion, a 20.6% increase year-over-year and the fifth consecutive month-to-month improvement. Demand was particularly strong in the U.S. and Asia. China&#39;s assertive stimulus policy has prompted a surge in domestic chipmaker stocks in recent weeks, which is not reflected in August&#39;s global sales figures.</p>
<p>Bets on individual semiconductor makers have been a popular choice for many investors, with NVDA shares nearly tripling in the last year and both TSM and AVGO stocks more than doubling during that time. Some investors may prefer a broader approach, though, to capitalize on the ongoing surge in the U.S. or the global semiconductor spaces. In these cases, there are a number of ETFs providing different types of exposure to this market.</p>
<h2><strong>SMH: Top-Performing Non-Leveraged Chip ETF</strong></h2>
<p>The <strong>VanEck Semiconductor ETF</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smh#NASDAQ">SMH</a>) provides reasonably broad coverage of the semiconductor space by targeting more than two dozen U.S.-listed chipmakers. Setting it apart from other U.S.-focused semiconductor funds is SMH&#39;s inclusion of chip manufacturers of different market capitalization levels, allowing for exposure beyond the largest companies.</p>
<p>SMH has outperformed all other non-leveraged semiconductor ETFs year-to-date, with a total return of nearly 42% in that time and a one-year increase of more than 68%. In the competitive ETF space, where fees for funds are often driven lower, SMH has a moderate expense ratio of 0.35%. This is in line with several other ETFs with a similar focus. VanEck&#39;s semiconductor fund also has a healthy asset base of more than $24 billion and strong liquidity based on average trading volumes.</p>
<h2><strong>SOXQ: Low Fee Alternative</strong></h2>
<p>The <strong>Invesco PHLX Semiconductor ETF</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soxq#NASDAQ">SOXQ</a>) is just a few years old, making it one of the newest semiconductor-focused funds available. It focuses on a pool of about 30 U.S.-listed and large-cap semiconductor companies, with major players like NVIDIA and Broadcom representing outsized portions of the portfolio.</p>
<p>SOXQ sets itself apart by its expense ratio of just 0.19%. The fund has undercut many other established semiconductor ETFs, drawing cost-conscious investors and those interested in buying and holding.</p>
<p>Given its smaller assets under management and lower liquidity levels than better-known rivals, a buy-and-hold strategy may also be best for SOXQ.</p>
<h2><strong>SEMI: Global Exposure</strong></h2>
<p>While many semiconductor ETFs focus on a small pool of U.S. companies, the <strong>Columbia Seligman Semiconductor &amp; Technology ETF</strong> (ARCA:SEMI) provides global exposure.</p>
<p>Although its portfolio remains relatively small, at about 30 holdings, and major players like NVIDIA still dominate, SEMI is nonetheless one of the most diverse semiconductor funds available.</p>
<p>This diversity gives investors access to a broader range of growth opportunities. By including international companies, SEMI stands out from other funds with a more limited geographic focus.</p>
<h2><strong>SOXL: Leveraged Semiconductor Fund</strong></h2>
<p>Investors looking to take a more active approach to trading may wish to make use of leveraged funds. In this area, the <strong>Direxion Daily Semiconductor Bull 3X Shares ETF</strong> (ARCA:SOXL) stands out for its 3x-long exposure to a pool of top U.S. semiconductor companies. SOXL dominates the leveraged semiconductor ETF space in terms of liquidity, which is key for investors because the fund&#39;s leverage resets daily.</p>
<p>This daily reset means traders must be cautious of volatility over multiple days, as the compounding effect can significantly impact overall returns. For this reason, SOXL is generally best suited for short-term trades rather than long-term holds, allowing investors to take advantage of sharp price movements in semiconductor stocks without holding the risks of daily compounding over an extended period.</p>
<h2><strong>Rotation Back Into Semiconductor Stocks?</strong></h2>
<p>Some investors shifted away from semiconductors ahead of the Fed&#39;s September rate cut. SMH and other semiconductor funds tumbled in July as a result. However, in the final quarter of the year it appears that semiconductor firms are back on track for continued gains, although the industry remains heavily dependent on a small number of very large names. ETFs focused in this space can help to mitigate the risk of individual chipmakers while still providing exposure to the industry as it continues to heat up.</p>
<p>The article &quot;<a href="https://www.marketbeat.com/stock-ideas/4-best-etfs-for-capitalizing-on-the-semiconductor-market-surge/">4 Best ETFs for Capitalizing on the Semiconductor Market Surge</a>&quot; first appeared on MarketBeat.</p>


Sector ETFs

ETFs

AVGO

SEMI

SOXL

SOXQ

4 Best ETFs for Capitalizing on the Semiconductor Market Surge

<p>Roth MKM  analyst Craig Irwin   reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Neutral and maintains $85 price target.</p>


Roth MKM Reiterates Neutral on Tesla, Maintains $85 Price Target

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>W.W. Grainger</strong>.</p>
<p>Looking at options history for W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with bullish expectations and 63% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $250,903 and 6, calls, for a total amount of $330,308.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $960.0 to $1100.0 for W.W. Grainger over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for W.W. Grainger's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of W.W. Grainger's whale trades within a strike price range from $960.0 to $1100.0 in the last 30 days. </p>
<h3>W.W. Grainger Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728666228_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GWW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$83.7</td>
<td>$76.9</td>
<td>$80.97</td>
<td>$1000.00</td>
<td>$89.0K</td>
<td style="text-align: right;">103</td>
<td style="text-align: right;">63</td>
</tr>
<tr>
<td>GWW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$64.9</td>
<td>$60.7</td>
<td>$62.29</td>
<td>$1060.00</td>
<td>$68.5K</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">21</td>
</tr>
<tr>
<td>GWW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.2</td>
<td>$10.7</td>
<td>$12.7</td>
<td>$980.00</td>
<td>$63.5K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">222</td>
</tr>
<tr>
<td>GWW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.4</td>
<td>$9.9</td>
<td>$12.0</td>
<td>$980.00</td>
<td>$57.6K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">48</td>
</tr>
<tr>
<td>GWW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$12.5</td>
<td>$10.1</td>
<td>$12.2</td>
<td>$980.00</td>
<td>$56.1K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">268</td>
</tr>
</tbody>
</table>
</p>
<h3>About W.W. Grainger</h3>
<p>W.W. Grainger distributes maintenance, repair, and operating products that are sourced from over 5,000 suppliers. The company serves more than 4.5 million customers through its online and electronic purchasing platforms, vending machines, catalog distribution, and network of over 300 global branches.</p>
<p>In light of the recent options history for W.W. Grainger, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of W.W. Grainger</h3>
<ul>
<li>With a trading volume of 207,505, the price of GWW is up by 5.62%, reaching $1082.78.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 20 days from now.</li>
</ul>
<h3>What The Experts Say On W.W. Grainger</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $925.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities downgraded its action to Underperform with a price target of $925. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest W.W. Grainger options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Decoding W.W. Grainger's Options Activity: What's the Big Picture?

<p><a href="https://fccid.io/2BBYK-LCD008" title="https://fccid.io/2BBYK-LCD008">https://fccid.io/2BBYK-LCD008</a></p>


LUCY

Innovative Eyewear Has Been Granted FCC Approval For New Versions Of Its ChatGPT Enabled Eyewear

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>DraftKings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DKNG, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for DraftKings.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 46% bullish and 53%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $605,250, and 10 are calls, for a total amount of $507,000.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $34.0 and $50.0 for DraftKings, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for DraftKings options trades today is 948.0 with a total volume of 4,060.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for DraftKings's big money trades within a strike price range of $34.0 to $50.0 over the last 30 days.</p>
<h3>DraftKings Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728666223_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.9</td>
<td>$7.8</td>
<td>$7.9</td>
<td>$45.00</td>
<td>$209.3K</td>
<td>2.2K</td>
<td style="text-align: right;">265</td>
</tr>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$12.15</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$50.00</td>
<td>$163.2K</td>
<td>3</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$11.35</td>
<td>$11.2</td>
<td>$11.35</td>
<td>$49.00</td>
<td>$129.3K</td>
<td>16</td>
<td style="text-align: right;">126</td>
</tr>
<tr>
<td>DKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$7.5</td>
<td>$7.35</td>
<td>$7.4</td>
<td>$34.00</td>
<td>$81.4K</td>
<td>544</td>
<td style="text-align: right;">111</td>
</tr>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.8</td>
<td>$7.7</td>
<td>$7.8</td>
<td>$45.00</td>
<td>$75.6K</td>
<td>2.2K</td>
<td style="text-align: right;">397</td>
</tr>
</tbody>
</table>
</p>
<h3>About DraftKings</h3>
<p>DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in 27 states and iGaming in seven states, with both products available to around 40% of Canada's population. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.</p>
<p>Having examined the options trading patterns of DraftKings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of DraftKings</h3>
<ul>
<li>Trading volume stands at 2,519,468, with DKNG's price up by 1.83%, positioned at $38.73.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 20 days.</li>
</ul>
<h3>What Analysts Are Saying About DraftKings</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $50.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $44.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $60.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on DraftKings, maintaining a target price of $54.<br />
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for DraftKings, targeting a price of $50.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for DraftKings, targeting a price of $45. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DraftKings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


DKNG

A Closer Look at DraftKings's Options Market Dynamics

<p>High-rolling investors have positioned themselves bearish on Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SPOT often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for Spotify Technology. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 37% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $60,060, and 7 calls, totaling $303,545.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $350.0 to $410.0 for Spotify Technology over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Spotify Technology's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Spotify Technology's significant trades, within a strike price range of $350.0 to $410.0, over the past month.</p>
<h3>Spotify Technology Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728666218_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$5.6</td>
<td>$5.5</td>
<td>$5.55</td>
<td>$377.50</td>
<td>$101.0K</td>
<td>121</td>
<td style="text-align: right;">184</td>
</tr>
<tr>
<td>SPOT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.2</td>
<td>$2.04</td>
<td>$2.2</td>
<td>$365.00</td>
<td>$60.0K</td>
<td>1.4K</td>
<td style="text-align: right;">398</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$12.45</td>
<td>$11.0</td>
<td>$11.0</td>
<td>$410.00</td>
<td>$48.4K</td>
<td>1.6K</td>
<td style="text-align: right;">103</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$2.92</td>
<td>$2.91</td>
<td>$2.92</td>
<td>$385.00</td>
<td>$40.6K</td>
<td>1.7K</td>
<td style="text-align: right;">145</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$12.45</td>
<td>$10.5</td>
<td>$11.05</td>
<td>$410.00</td>
<td>$29.8K</td>
<td>1.6K</td>
<td style="text-align: right;">130</td>
</tr>
</tbody>
</table>
</p>
<h3>About Spotify Technology</h3>
<p>Spotify, headquartered in Stockholm, Sweden, is one of the world's largest music streaming service providers, with 602 million monthly active users at the end of 2023. The firm monetizes its users through a paid subscription model, referred to as its premium service, and an ad-based model, referred to as its ad-supported service. Revenue from premium and ad-supported services represented 86% and 14% of Spotify's 2023 total revenue, respectively.</p>
<p>After a thorough review of the options trading surrounding Spotify Technology, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Spotify Technology</h3>
<ul>
<li>Currently trading with a volume of 403,128, the SPOT's price is down by -0.97%, now at $374.34. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 32 days.</li>
</ul>
<h3>What The Experts Say On Spotify Technology</h3>
<p>Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $407.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Pivotal Research keeps a Buy rating on Spotify Technology with a target price of $510.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Spotify Technology with a target price of $440.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $340.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $340.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Spotify Technology options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


SPOT

Spotify Technology's Options Frenzy: What You Need to Know

<p>In the preceding three months, 6 analysts have released ratings for Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $33.17, along with a high estimate of $41.00 and a low estimate of $27.00. Witnessing a positive shift, the current average has risen by 28.82% from the previous average price target of $25.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728666198_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Nurix Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Song</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Breidenbach</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Mark Breidenbach</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Nurix Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Nurix Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Nurix Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Nurix Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NRIX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Nurix Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Nurix Therapeutics</h2>
<p>Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.</p>
<h3>Nurix Therapeutics's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Nurix Therapeutics faced challenges, resulting in a decline of approximately <strong>-60.58%</strong> in revenue growth as of 31 May, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Nurix Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of <strong>-368.39%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Nurix Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-16.52%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Nurix Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-10.82%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Nurix Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.08</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NRIX

Unveiling 6 Analyst Insights On Nurix Therapeutics

Macro Economic Events

Econ #s

Economics

U.S. Baker Hughes Oil Rig Count +2 To 481 Vs 479 Prior; U.S. Baker Hughes NatGas Rig Count -1; U.S. Baker Hughes Total Rig Count 586 Vs 585 Prior

<p>5 analysts have expressed a variety of opinions on Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $75.0, a high estimate of $91.00, and a low estimate of $61.00. Highlighting a 13.04% decrease, the current average has fallen from the previous average price target of $86.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728666174_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Valaris's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Announces</td>
<td>Neutral</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Nikhil Gupta</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$71.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Valaris. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Valaris compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Valaris's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Valaris's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VAL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Valaris analyst ratings.</strong></a></p>
<h2>Delving into Valaris's Background</h2>
<p>Valaris Ltd is the industry leader in offshore drilling services across all water depths and geographies. It is a high-quality rig fleet of ultra-deepwater drillships, versatile semisubmersibles and modern shallow-water jackups. It operates in Floaters, Jackups, ARO and Others. Its majority of the revenue comes from Floaters segment which includes drillships and semisubmersible rigs.</p>
<h3>Financial Insights: Valaris</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Valaris's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>46.94%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Valaris's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>24.52%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Valaris's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.13%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Valaris's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.41%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Valaris's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.53</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Critical Insights From Valaris Analyst Ratings: What You Need To Know

Longleaf Partners International Fund Q4 2023 Commentary

Analyst Anne Ling of Jefferies maintained a Buy rating on WH Group Limited (WHGRF – Research Report), with a price target of HK$5.84. Anne Ling's B...

WH Group Limited: Strong Buy Rating Amid Recovery and Profitability Growth Prospects

Mavis Hui, an analyst from DBS, maintained the Buy rating on WH Group Limited (WHGRF – Research Report). The associated price target is HK$5.34. Ma...

Buy Rating for WH Group Limited: Strong Market Position and Strategic Expansion Fuel Positive Outlook

Anne Ling, an analyst from Jefferies, maintained the Buy rating on WH Group Limited (WHGRF – Research Report). The associated price target is HK$6....

WH Group Limited: A Strong Buy on Robust Packaged Meat Business and Strategic Profitability Improvements

Analyst Anne Ling of Jefferies maintained a Buy rating on WH Group Limited (WHGRF – Research Report), retaining the price target of HK$6.21. Anne L...

Buy Rating Affirmed for WH Group Limited on Strong US Performance and Robust Profit Growth

Longleaf Partners International Fund Q1 2024 Commentary

WH Group Ltd ADR: Where Pigs Make Money

No hot dog for you! Joey Chestnut banned from Nathan's iconic contest - update

Smithfield Foods to be listed on U.S. exchange, Chinese parent says

Wall Street Breakfast Podcast: Google Reportedly Near $23B Wiz Purchase

ACCYY

ACRFF

APLUF

BABA

BABAF

BCCLF

CKHUF

CKHUY

DELHY

DLVHF

DMZPY

DPZUF

EXXRF

FAXRF

FAXXF

FFHPF

FRFFF

FRFGF

FRFHF

FRFXF

FRFZF

FXFHF

FXFLF

GGROW

GLAPF

GLAPY

GMKKY

GOOG

GOOGL

GPAGF

GREE

GREEL

JVTSF

KPTCY

KSANF

LNXSF

LNXSY

MAWHF

MAWHY

MDEVF

MDEVY

NATH

NHNCF

PFODF

PROSF

PROSY

PRRFY

WH Group

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

WH Group

WH Group (WHGLY) Forecast

WH Group (OTC:WHGLY) Stock, Quote.Headers.trade-ideas